Immunome (IMNM) Is Up 11.7% After Phase 3 Varegacestat Success - Has The Bull Case Changed? [Yahoo! Finance]
Immunome, Inc. (IMNM)
Company Research
Source: Yahoo! Finance
progression versus placebo and plans to seek FDA approval in the second quarter of 2026. This outcome positions Varegacestat as a potentially important therapy candidate, with Phase 3 evidence that may support Immunome's broader clinical and regulatory ambitions. Next, we'll examine how Immunome's Phase 3 Varegacestat success could influence the company's investment narrative and future growth priorities. AI is about to change healthcare. These 108 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early. For Immunome, the big-picture belief now centers on Varegacestat as a potential foundation asset, rather than just another pipeline shot on goal. The strong Phase 3 RINGSIDE data materially reshapes the short-term story: the planned FDA filing in 2026 becomes a key catalyst, and investors are likely to focus more on regulatory milestones, label scope and launch readin
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Assessing Immunome (IMNM) Valuation After Recent Share Price Momentum And Conflicting P/B And DCF Signals [Yahoo! Finance]Yahoo! Finance
- Is Immunome, Inc. (IMNM) The Best Booming Stock To Buy Right Now? [Yahoo! Finance]Yahoo! Finance
- Immunome (NASDAQ:IMNM) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $31.00 price target on the stock.MarketBeat
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Jim Cramer on Immunome: “If You Want to Speculate on It, Fine” [Yahoo! Finance]Yahoo! Finance
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 12/30/25 - Form 4
- 12/23/25 - Form 4
- 12/22/25 - Form SCHEDULE
- IMNM's page on the SEC website